» Articles » PMID: 28408996

Risk Factors for Complications After Ileocolonic Resection for Crohn's Disease with a Major Focus on the Impact of Preoperative Immunosuppressive and Biologic Therapy: A Retrospective International Multicentre Study

Abstract

Background: TY, AS, YS, FVT and PGK designed the study. All authors did data collection and gave scientific contribution to the study design and discussion. TY, AS and PGK drafted the article. All authors read and approved the final version of the manuscript.In the era of biologic agents, risk factors for complications following resection for Crohn's disease have not been fully identified. In particular, the association of preoperative use of immunosuppressive and biologic agents with the incidence of complications after resection remains to be elucidated.

Aim: This retrospective multicentre study aimed to identify risk factors for complications after ileocolonic resection for Crohn's disease, with a major focus on the impact of preoperative immunosuppressive and biologic therapy.

Methods: A total of 231 consecutive patients who underwent ileocolonic resections for active Crohn's disease in seven inflammatory bowel disease referral centres from three countries (Japan, Brazil and Italy) were included. The following variables were investigated as potential risk factors: age at surgery, gender, behaviour of Crohn's disease (perforating vs. non-perforating disease), smoking, preoperative use (within eight weeks before surgery) of steroids, immunosuppressants and biologic agents, previous resection, blood transfusion, surgical procedure (open vs. laparoscopic approach), and type of anastomosis (side-to-side vs. end-to-end). Postoperative complications occurring within 30 days after surgery were recorded.

Results: The rates of overall complications, intra-abdominal sepsis, and anastomotic leak were 24%, 12% and 8%, respectively. Neither immunosuppressive nor biologic therapy prior to surgery was significantly associated with the incidence of overall complications, intra-abdominal sepsis or anastomotic leak. In multivariate analysis, blood transfusion, perforating disease and previous resection were significant risk factors for overall complications (odds ratio [OR] 3.02, 95% confidence interval [CI] 1.21-7.52;  = 0.02), intra-abdominal sepsis (OR 2.67, 95% CI 1.04-6.86;  = 0.04) and anastomotic leak (OR 2.87, 95% CI 1.01-8.18;  = 0.048), respectively.

Conclusions: Blood transfusion, perforating disease and previous resection were significant risk factors for overall complications, intra-abdominal sepsis and anastomotic leak after ileocolonic resection for Crohn's disease, respectively. Preoperative immunosuppressive or biologic therapy did not increase the risk of postoperative complications.

Citing Articles

Safety and Efficacy of Infusional Perioperative Tacrolimus Therapy in Crohn's Disease Patients Undergoing Intestinal Resection.

Beck M, Schomburg N, Albers M, Bartsch D, Knapp N, Granseyer J Inflamm Intest Dis. 2025; 10(1):18-33.

PMID: 39816325 PMC: 11735035. DOI: 10.1159/000542443.


Risk factors for anastomotic complications after elective intestinal resection in Crohn's disease.

Atici A, Ozocak A, Karpuz G, Sevindi H, Daganci S, Yegen S Turk J Surg. 2024; 40(2):136-144.

PMID: 39628509 PMC: 11610615. DOI: 10.47717/turkjsurg.2024.6417.


Postoperative outcomes of surgical delay in inflammatory bowel disease patients: a multicenter cohort study.

de Bock E, Herman E, Meij V, Burghgraef T, Oldenburg B, Verheijen P Updates Surg. 2024; 76(4):1271-1277.

PMID: 38805172 PMC: 11341736. DOI: 10.1007/s13304-024-01893-5.


Predicting short-term major postoperative complications in intestinal resection for Crohn's disease: A machine learning-based study.

Wang F, Lin Y, Yuan X, Gao R, Wu X, Xu W World J Gastrointest Surg. 2024; 16(3):717-730.

PMID: 38577067 PMC: 10989335. DOI: 10.4240/wjgs.v16.i3.717.


Preoperative screening and prehabilitation strategies prior to ileocolic resection in patients with Crohn's disease are not incorporated in routine care.

Bak M, van Ruler O, Stassen L, Ruiterkamp M, Arkenbosch J, Dijkstra G Int J Colorectal Dis. 2023; 38(1):254.

PMID: 37855846 PMC: 10587192. DOI: 10.1007/s00384-023-04537-z.


References
1.
Marchal L, DHaens G, Van Assche G, Vermeire S, Noman M, Ferrante M . The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004; 19(7):749-54. DOI: 10.1111/j.1365-2036.2004.01904.x. View

2.
Krane M, Allaix M, Zoccali M, Umanskiy K, Rubin M, Villa A . Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease. Dis Colon Rectum. 2013; 56(4):449-57. DOI: 10.1097/DCR.0b013e3182759029. View

3.
Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

4.
Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz L . Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2012; 18(12):2404-13. DOI: 10.1002/ibd.22954. View

5.
Greenstein A, Lachman P, Sachar D, Springhorn J, Heimann T, Janowitz H . Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut. 1988; 29(5):588-92. PMC: 1433651. DOI: 10.1136/gut.29.5.588. View